Loading...
•
Mar 30, 2025
Maxcyte Q1 2025 Earnings Report
MaxCyte reported its first quarter 2025 financial results, showing a decrease in total revenue but an increase in core business revenue.
Key Takeaways
MaxCyte reported a total revenue of $10.4 million for the first quarter of 2025, an 8% decrease compared to the same period in 2024. However, core business revenue increased by 1% to $8.2 million. The company added one new SPL client, TG Therapeutics, bringing the total number of active SPLs to 29. Net loss for the quarter was $10.3 million.
Total revenue for Q1 2025 was $10.4 million, an 8% decrease from Q1 2024.
Core business revenue increased by 1% to $8.2 million in Q1 2025.
Strategic Platform License (SPL) Program-related revenue decreased by 32% to $2.1 million.
MaxCyte added one new SPL client, TG Therapeutics, bringing the total active SPLs to 29.
Revenue by Segment
Forward Guidance
MaxCyte reiterates its 2025 revenue guidance, expecting core revenue to grow 8% to 15% compared to 2024, and SPL Program-related revenue to be approximately $5 million for the year. The company anticipates ending 2025 with approximately $160 million in total cash, cash equivalents, and investments.
Positive Outlook
- Core revenue is expected to grow 8% to 15% compared to 2024, including revenue from SeQure Dx.
- SPL Program-related revenue is expected to be approximately $5 million for the year.
- SPL-program related revenue guidance includes expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments.
- MaxCyte expects to end 2025 with approximately $160 million in total cash, cash equivalents and investments.
- Continued focus on disciplined investments in high growth opportunities and process enhancements.
Challenges Ahead
- No specific negative guidance points were provided in the report.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...